Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

68 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.
Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. Pellegrini M, et al. Among authors: groth n. Vaccine. 2009 Nov 16;27(49):6959-65. doi: 10.1016/j.vaccine.2009.08.101. Epub 2009 Sep 12. Vaccine. 2009. PMID: 19751689
Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review.
Muturi-Kioi V, Lewis D, Launay O, Leroux-Roels G, Anemona A, Loulergue P, Bodinham CL, Aerssens A, Groth N, Saul A, Podda A. Muturi-Kioi V, et al. Among authors: groth n. PLoS One. 2016 Aug 4;11(8):e0157385. doi: 10.1371/journal.pone.0157385. eCollection 2016. PLoS One. 2016. PMID: 27490698 Free PMC article. Review.
Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy.
Mannino S, Villa M, Apolone G, Weiss NS, Groth N, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Rothman KJ. Mannino S, et al. Among authors: groth n. Am J Epidemiol. 2012 Sep 15;176(6):527-33. doi: 10.1093/aje/kws313. Epub 2012 Aug 31. Am J Epidemiol. 2012. PMID: 22940713 Free PMC article. Clinical Trial.
Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy.
Villa M, Black S, Groth N, Rothman KJ, Apolone G, Weiss NS, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Crucitti A, Della Cioppa G, Scarpini E, Mavilio D, Mannino S. Villa M, et al. Among authors: groth n. Am J Epidemiol. 2013 Oct 1;178(7):1139-45. doi: 10.1093/aje/kwt078. Epub 2013 Jul 17. Am J Epidemiol. 2013. PMID: 23863759 Free PMC article.
A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli C, Groth N, Levin Y, Del Giudice G. Della Cioppa G, et al. Among authors: groth n. Hum Vaccin Immunother. 2014;10(6):1701-10. doi: 10.4161/hv.28618. Epub 2014 Apr 14. Hum Vaccin Immunother. 2014. PMID: 24732325 Free PMC article.
Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.
Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli G, Groth N, Del Giudice G. Della Cioppa G, et al. Among authors: groth n. Hum Vaccin Immunother. 2012 Feb;8(2):216-27. doi: 10.4161/hv.18445. Epub 2012 Feb 1. Hum Vaccin Immunother. 2012. PMID: 22426371 Clinical Trial.
MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis.
Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. Banzhoff A, et al. Among authors: groth n. Influenza Other Respir Viruses. 2008 Nov;2(6):243-9. doi: 10.1111/j.1750-2659.2008.00059.x. Influenza Other Respir Viruses. 2008. PMID: 19453401 Free PMC article. Review.
Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Reisinger KS, et al. Among authors: groth n. J Infect Dis. 2009 Sep 15;200(6):849-57. doi: 10.1086/605506. J Infect Dis. 2009. PMID: 19673652 Clinical Trial.
METHODS: Adult subjects (n = 613; 18 to <50 years of age) were randomized (1:1) to receive either CCIV or TIV. The safety and reactogenicity of the 2 vaccines were assessed on the basis of solicited indicators and other adverse events (AEs) within 7 days of vaccination. …
METHODS: Adult subjects (n = 613; 18 to <50 years of age) were randomized (1:1) to receive either CCIV or TIV. The safety and reac …
Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.
Solares AR, Aragon CG, Pivaral RU, Prado-Cohrs D, Sales-Carmona V, Pellegrini M, Groth N. Solares AR, et al. Among authors: groth n. J Infect Dev Ctries. 2014 Sep 12;8(9):1160-8. doi: 10.3855/jidc.4594. J Infect Dev Ctries. 2014. PMID: 25212080 Free article. Clinical Trial.
A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic.
Reynales H, Astudillo P, de Vallière S, Hatz C, Schlagenhauf P, Rath B, Velentgas P, Fariña A, Sales-Carmona V, Groth N. Reynales H, et al. Among authors: groth n. Vaccine. 2012 Oct 5;30(45):6436-43. doi: 10.1016/j.vaccine.2012.08.005. Epub 2012 Aug 15. Vaccine. 2012. PMID: 22902681
68 results
Jump to page
Feedback